Clinical trial
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With…
NCT00450814 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00450814 |
|---|---|
| Title | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma |
| Official title | Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma |
| Intervention type | Biological, Drug, Other |
| Interventions | Cyclophosphamide, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Pharmacological Study |
| Enrollment | 48 |
| Start date | Nov 30, 2006 |
| Primary completion | Jul 10, 2018 |
| Completion | Nov 20, 2019 |
| First posted | Mar 22, 2007 |
| Last update posted | Dec 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: